shot-button
Subscription Subscription
Home > Sports News > Other Sports News > Article > Sprinter Caster Semenya loses appeal over CAS ruling

Sprinter Caster Semenya loses appeal over CAS ruling

Updated on: 10 September,2020 07:55 AM IST  |  Laussane
AFP |

World Athletics banned Semenya and other DSD athletes from races between 400m and a mile unless they take testosterone-reducing drugs.

Sprinter Caster Semenya loses appeal over CAS ruling

Caster Semenya

South Africa's double Olympic 800m champion Caster Semenya cannot compete until she accepts to be treated with hormone-suppressing drugs, the Swiss supreme court confirmed on Tuesday. The court dismissed the appeals submitted by Semenya and her athletics federation against the decision by the Court of Arbitration for Sport on eligibility regulations for differences of sexual development (DSD) athletes. "The Court of Arbitration for Sport had the right to uphold the conditions of participation issued for female athletes with the genetic variant '46 XY DSD' in order to guarantee fair competition for certain running disciplines in female athletics," the Swiss court said.


World Athletics banned Semenya and other DSD athletes from races between 400m and a mile unless they take testosterone-reducing drugs. Semenya is classified as a woman, was raised as a woman and races as a woman. But for World Athletics, women like Semenya, with certain masculine attributes due to DSD, are classified, biologically, as men. It is a position hotly contested by South African officials. In the build-up to the 2009 world championships in Berlin, where an 18-year-old Semenya went on to win gold in the 800m, the South African had to undergo gender verification testing to confirm her eligibility to compete in the women's category. She was subsequently put on medication to reduce her testosterone levels, spending six months sidelined by World Athletics.


Semenya, born with the "46 XY" chromosome rather than the XX chromosome most females have, described the experience as like that of being treated like a "human guinea pig" and vowed never to again allow World Athletics (then known as the IAAF) to enforce medication upon her in order to compete. And after Tuesday's ruling in Switzerland, Semenya again refused to comply, even though it might mean missing out on the Tokyo Olympics, postponed until 2021 because of the coronavirus pandemic. "I am very disappointed by this ruling, but refuse to let World Athletics drug me or stop me from being who I am," she said.


"Excluding female athletes or endangering our health solely because of our natural abilities puts World Athletics on the wrong side of history. "I will continue to fight for the human rights of female athletes, both on the track and off the track, until we can all run free the way we were born. I know what is right and will do all I can to protect basic human rights, for young girls everywhere." Dorothee Schramm, the lawyer who led Semenya's appeal, said the decision was a "call to action - as a society, we cannot allow a sports federation to override the most fundamental of human rights".

Keep scrolling to read more news

Catch up on all the latest sports news and updates here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK